Immucell Corp Dossier - Source-backed chat

Immucell Corp

ICCCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.70

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $9.60Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $87.2M

Enterprise Value $86.6M

Shares Outstanding 9.1M diluted

Moat Rating Narrow

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ImmuCell Corporation (Nasdaq: ICCC) represents a compelling pure-play animal health biologics investment. Following a strategic pivot in late 2025 to pause further investments in its mastitis product candidate, Re-Tain, the company has successfully focused 100% of its resources on its market-leading First Defense calf scours prevention franchise. This strategic concentration is already yielding record results, as evidenced by a historic Q1 2026 where product sales exceeded $10 million for the first time, driven by strong seasonal demand, yield improvements, and market share gains. Supported by a $2 million litigation settlement to fund capacity expansion and a highly experienced leadership team, ImmuCell is well-positioned to capitalize on historically high newborn calf values and expand its market share in the scours biologicals sector.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, a sharp decline in dairy and beef calf prices reduces the economic incentive for producers to invest in premium preventative health programs, leading to flat or declining First Defense sales. Manufacturing yield improvements stall, or a recurrence of past production contamination issues limits product availability. Additionally, international sales remain sluggish due to persistent regulatory or distribution hurdles.

Base CaseCentral scenario

Under the base case, ImmuCell continues to execute on its First Defense-focused strategy, leveraging yield improvements to meet robust domestic demand. The company successfully deploys its $2 million settlement to expand manufacturing capacity toward 5-6 million units annually. High calf values persist, sustaining strong customer demand for premium scours prevention. Gross margins stabilize in the 43%-46% range, and international sales recover as Canadian order timing normalizes.

Bull CaseUpside scenario

ImmuCell's strategic pivot to focus 100% of its resources on the high-margin First Defense product line is driving strong operational performance, as evidenced by its first-ever $10M+ revenue quarter in Q1 2026 (up 28.4% YoY) and Q2 2026 sales growth of 11.5% YoY. By expanding its sales force by 50% and repurposing Re-Tain assets to increase First Defense production capacity, the company is well-positioned to capture a larger share of the estimated $900 million global scours prevention market.

Scenarios reflect our research view at the research date.

Key Investment Merits

Pure-play focus on the highly profitable and growing First Defense calf scours prevention franchise.
Record financial performance in Q1 2026 with product sales growing 28.4% YoY to $10.4 million and gross margins expanding to 45.0%.
Strong balance sheet with cash rising to $6.8 million as of March 31, 2026, bolstered by $3.4 million in free cash flow and a $2 million contract manufacturer settlement.
Favorable macroeconomic tailwinds, including historically high newborn calf values that increase the ROI of preventative calf health programs for producers.
Significant manufacturing efficiency gains, with average monthly output increasing from 380,000 units in 2025 to over 450,000 units in Q1 2026.

Key Investment Risks

Concentration risk, with the First Defense product line accounting for approximately 99% of total product sales.
Sensitivity of demand to dairy and beef commodity cycles and calf market prices.
Potential manufacturing vulnerabilities, including yield volatility or contamination risks inherent in biological production.
Sluggish international sales, which declined 30.2% in Q1 2026 due to order timing and distribution challenges.

Thesis Invalidation Triggers

A sustained drop in gross margins below 38% due to manufacturing inefficiencies or cost inflation.
A severe biological contamination event at the Portland manufacturing facility that halts production for more than one quarter.
A decline in quarterly product sales below $7.5 million during peak seasonal quarters.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.